Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.

In vitro comparative quality assessment of different brands of norfloxacin tablets available in Jimma, Southwest Ethiopia

Open access
Hambisa, Solomon, Belew, Sileshi, Suleman, Sultan · 2019 · Drug Design Development and Therapy

Abstract

BACKGROUND: Pharmaceuticals play a pivotal role in maintaining human health and promoting well-being. However, safety, efficacy, and quality of the drugs should be ascertained to provide a desired pharmacological effect. AIM: The aim of the present study was to determine the quality as well as the physicochemical equivalence of nine brands of norfloxacin tablets marketed in Jimma, Ethiopia. METHODS: Nine norfloxacin brands were subjected to in vitro tests associated with quality of tablet dosage form, and the tests were conducted according to procedures described in the United States Pharmacopeia (USP). RESULTS: This study indicated that all brands of norfloxacin complied with the USP for uniformity of weight, friability, hardness, and assay of active ingredient. However, two of the nine brands evaluated failed to release 80% of their drug contents within 30 minutes as outlined in the USP. Correspondingly, all of the brands studied were within the specification for hardness test. Furthermore, different dissolution profile comparison methods have proven the similarity in dissolution profile of Negaflox and Norcin with the comparator product (Trizolin). Mathematical models-dependent approaches have shown that the drug release data fit well to the Weibull release model. CONCLUSION: The physicochemical evaluation showed that all the norfloxacin brands met the quality specification with respect to uniformity of weight, hardness, friability, and assay. With regard to dissolution test, two brands of norfloxacin were found to be out of the specified pharmacopeial requirement. The study also revealed the similarity in the dissolution profile of two brands of norfloxacin with the comparator product.

Overview

CoChat Summary

## TL;DR

This in vitro study compared nine 400 mg norfloxacin tablet brands marketed in Jimma, Ethiopia using USP-based quality tests. All brands passed weight variation, hardness, friability, and assay criteria, but two brands failed the USP dissolution requirement and only three brands (N1, N5, N7) were judged interchangeable with the comparator based on dissolution-profile comparisons.

## Key findings

  • All nine brands met USP specifications for uniformity of weight, hardness, friability, and assay of active ingredient.
  • Two of nine brands failed the USP dissolution criterion of releasing not less than 80% within 30 minutes: N3 (77.05%) and N8 (74.45%).
  • In dissolution-profile comparison, N1, N5, and N7 were similar to the comparator (N9) by multiple metrics: f2 > 50, f1 < 15, and DE differences within ±10%.
  • The authors report that drug-release data for all brands fit best to the Weibull model.

## Methods

  • Design/sample: Laboratory-based comparative in vitro evaluation of nine norfloxacin tablet brands (all 400 mg) purchased from licensed retail outlets and a hospital pharmacy in Jimma, Ethiopia; one marketed product (N9) served as the comparator because the innovator product was unavailable.
  • Tests performed: USP-based weight variation (20 tablets/brand), friability (20 tablets/brand), hardness (10 tablets/brand), assay by HPLC, and dissolution testing (6 tablets/brand).
  • Analysis: Descriptive comparison plus one-way ANOVA (and Dunnett’s test for comparator comparisons), f1/f2 similarity factors, dissolution efficiency (DE), and fitting of release data to zero-order, first-order, Higuchi, Hixson–Crowell, and Weibull models.

## Limitations

  • The paper does not state formal study limitations.
  • Evident from the text: this was an in vitro study only, so it does not directly measure in vivo bioequivalence or clinical outcomes.
  • Evident from the text: the comparator was not the innovator product; it was a marketed product selected because the innovator was unavailable in the Ethiopian market.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/dddt.s189524

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Calibration curve of norfloxacin reference standard in the concentration range of 160–240 µg/mL.
Figure 1 Calibration curve of norfloxacin reference standard in the concentration range of 160–240 µg/mL.CC BY-NC · PubMed Central
Figure 2 Calibration curve of norfloxacin reference standard in the concentration range of 1–6 µg/mL.
Figure 2 Calibration curve of norfloxacin reference standard in the concentration range of 1–6 µg/mL.CC BY-NC · PubMed Central
Figure 3 Comparative in vitro dissolution profiles of different brands of norfloxacin tablet. Abbreviations: N1, Negaflox; N2, Norfen; N3, Asnor; N4, Norbek; N5, Norcin; N6, Uriflox; N7, Gyrablock; N8, Norflox; N9, Trizolin.
Figure 3 Comparative in vitro dissolution profiles of different brands of norfloxacin tablet. Abbreviations: N1, Negaflox; N2, Norfen; N3, Asnor; N4, Norbek; N5, Norcin; N6, Uriflox; N7, Gyrablock; N8, Norflox; N9, Trizolin.CC BY-NC · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 18 Not checked · 19 Own results and interpretations

19 more claims

Create a free account to see all 37 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 10
  • The quote only partly states this claim. 3
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Cited by

See all 30

Metadata

Authors
Hambisa, S., Belew, S., & Suleman, S.
Affiliations
Jimma University (ET)
Corresponding author
Hambisa, Solomon
Venue
Drug Design Development and Therapy
Published
2019-04
Volume
Volume 13
Pages
1241-1249
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2940268474
Cited by
30
References
24
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 6 · 2020: 3
FWCI
3.68
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Jimma University
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
drug quality assessment, dissolution profile, weight uniformity, friability, tablet hardness, generic drug quality, Jimma, Ethiopia
MeSH terms
Anti-Bacterial Agents, Ethiopia, Kinetics, Norfloxacin, Quality Control, Tablets, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.